Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Proc Natl Acad Sci U S A ; 106(42): 17787-92, 2009 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-19805130

RESUMEN

We know a great deal about the cellular response to starvation via AMPK, but less is known about the reaction to nutrient excess. Insulin resistance may be an appropriate response to nutrient excess, but the cellular sensors that link these parameters remain poorly defined. In the present study we provide evidence that mitochondrial superoxide production is a common feature of many different models of insulin resistance in adipocytes, myotubes, and mice. In particular, insulin resistance was rapidly reversible upon exposure to agents that act as mitochondrial uncouplers, ETC inhibitors, or mitochondrial superoxide dismutase (MnSOD) mimetics. Similar effects were observed with overexpression of mitochondrial MnSOD. Furthermore, acute induction of mitochondrial superoxide production using the complex III antagonist antimycin A caused rapid attenuation of insulin action independently of changes in the canonical PI3K/Akt pathway. These results were validated in vivo in that MnSOD transgenic mice were partially protected against HFD induced insulin resistance and MnSOD+/- mice were glucose intolerant on a standard chow diet. These data place mitochondrial superoxide at the nexus between intracellular metabolism and the control of insulin action potentially defining this as a metabolic sensor of energy excess.


Asunto(s)
Antioxidantes/metabolismo , Resistencia a la Insulina/fisiología , Células 3T3-L1 , Adipocitos/efectos de los fármacos , Adipocitos/metabolismo , Animales , Antimicina A/farmacología , Antioxidantes/farmacología , Línea Celular , Resistencia a la Insulina/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Modelos Biológicos , Fibras Musculares Esqueléticas/efectos de los fármacos , Fibras Musculares Esqueléticas/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Superóxido Dismutasa/genética , Superóxido Dismutasa/metabolismo , Superóxidos/metabolismo
2.
Chem Biol ; 15(3): 263-73, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18355726

RESUMEN

Four cucurbitane glycosides, momordicosides Q, R, S, and T, and stereochemistry-established karaviloside XI, were isolated from the vegetable bitter melon (Momordica charantia). These compounds and their aglycones exhibited a number of biologic effects beneficial to diabetes and obesity. In both L6 myotubes and 3T3-L1 adipocytes, they stimulated GLUT4 translocation to the cell membrane--an essential step for inducible glucose entry into cells. This was associated with increased activity of AMP-activated protein kinase (AMPK), a key pathway mediating glucose uptake and fatty acid oxidation. Furthermore, momordicoside(s) enhanced fatty acid oxidation and glucose disposal during glucose tolerance tests in both insulin-sensitive and insulin-resistant mice. These findings indicate that cucurbitane triterpenoids, the characteristic constituents of M. charantia, may provide leads as a class of therapeutics for diabetes and obesity.


Asunto(s)
Hipoglucemiantes/aislamiento & purificación , Hipoglucemiantes/farmacología , Momordica charantia/química , Complejos Multienzimáticos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Transducción de Señal/efectos de los fármacos , Terpenos/aislamiento & purificación , Terpenos/farmacología , Células 3T3-L1 , Proteínas Quinasas Activadas por AMP , Adipocitos/efectos de los fármacos , Adipocitos/metabolismo , Adipocitos/ultraestructura , Animales , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Ácidos Grasos/metabolismo , Glucosa/metabolismo , Transportador de Glucosa de Tipo 4/metabolismo , Humanos , Hipoglucemiantes/química , Insulina/metabolismo , Ratones , Fibras Musculares Esqueléticas/efectos de los fármacos , Fibras Musculares Esqueléticas/metabolismo , Fibras Musculares Esqueléticas/ultraestructura , Oxidación-Reducción/efectos de los fármacos , Fosforilación/efectos de los fármacos , Terpenos/química
3.
Mol Endocrinol ; 22(12): 2703-15, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18801932

RESUMEN

Insulin-stimulated translocation of the glucose transporter GLUT4 to the plasma membrane in muscle and fat cells depends on the phosphatidylinositide 3-kinase/Akt pathway. The downstream target AS160/TBC1D4 is phosphorylated upon insulin stimulation and contains a TBC domain (Tre-2/Bub2/Cdc16) that is present in most Rab guanosine triphosphatase-activating proteins. TBC1D4 associates with GLUT4-containing membranes under basal conditions and dissociates from membranes with insulin. Here we show that the association of TBC1D4 with membranes is required for its inhibitory action on GLUT4 translocation under basal conditions. Whereas the insulin-dependent dissociation of TBC1D4 from membranes was not required for GLUT4 translocation, its phosphorylation was essential. Many agonists that stimulate GLUT4 translocation failed to trigger TBC1D4 translocation to the cytosol, but in most cases these agonists stimulated TBC1D4 phosphorylation at T642, and their effects on GLUT4 translocation were inhibited by overexpression of the TBC1D4 phosphorylation mutant (TBC1D4-4P). We postulate that TBC1D4 acts to impede GLUT4 translocation by disarming a Rab protein found on GLUT4-containing-membranes and that phosphorylation of TBC1D4 per se is sufficient to overcome this effect, allowing GLUT4 translocation to the cell surface to proceed.


Asunto(s)
Membrana Celular/fisiología , Proteínas Activadoras de GTPasa/fisiología , Transportador de Glucosa de Tipo 4/metabolismo , Células 3T3-L1 , Androstadienos/farmacología , Animales , Células CHO , Membrana Celular/metabolismo , Células Cultivadas , Cricetinae , Cricetulus , Citosol/efectos de los fármacos , Citosol/metabolismo , Proteínas Activadoras de GTPasa/química , Proteínas Activadoras de GTPasa/metabolismo , Insulina/farmacología , Ratones , Fibras Musculares Esqueléticas/efectos de los fármacos , Fibras Musculares Esqueléticas/metabolismo , Fibras Musculares Esqueléticas/fisiología , Fosforilación/efectos de los fármacos , Fosforilación/fisiología , Inhibidores de Proteínas Quinasas/farmacología , Estructura Terciaria de Proteína/fisiología , Transporte de Proteínas/efectos de los fármacos , Vesículas Transportadoras/metabolismo , Vesículas Transportadoras/fisiología , Wortmanina , Proteínas de Unión al GTP rab/metabolismo
4.
Diabetes ; 55(10): 2688-97, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17003332

RESUMEN

Although interleukin-6 (IL-6) has been associated with insulin resistance, little is known regarding the effects of IL-6 on insulin sensitivity in humans in vivo. Here, we show that IL-6 infusion increases glucose disposal without affecting the complete suppression of endogenous glucose production during a hyperinsulinemic-euglycemic clamp in healthy humans. Because skeletal muscle accounts for most of the insulin-stimulated glucose disposal in vivo, we examined the mechanism(s) by which IL-6 may affect muscle metabolism using L6 myotubes. IL-6 treatment increased fatty acid oxidation, basal and insulin-stimulated glucose uptake, and translocation of GLUT4 to the plasma membrane. Furthermore, IL-6 rapidly and markedly increased AMP-activated protein kinase (AMPK). To determine whether the activation of AMPK mediated cellular metabolic events, we conducted experiments using L6 myotubes infected with dominant-negative AMPK alpha-subunit. The effects described above were abrogated in AMPK dominant-negative-infected cells. Our results demonstrate that acute IL-6 treatment enhances insulin-stimulated glucose disposal in humans in vivo, while the effects of IL-6 on glucose and fatty acid metabolism in vitro appear to be mediated by AMPK.


Asunto(s)
Ácidos Grasos/metabolismo , Glucosa/metabolismo , Insulina/fisiología , Interleucina-6/farmacología , Complejos Multienzimáticos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Células 3T3-L1 , Proteínas Quinasas Activadas por AMP , Adulto , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/farmacología , Animales , Línea Celular , Membrana Celular/metabolismo , Técnica de Clampeo de la Glucosa , Transportador de Glucosa de Tipo 4 , Humanos , Hiperinsulinismo/fisiopatología , Interleucina-6/fisiología , Masculino , Ratones , Ratones Noqueados , Mioblastos , Ratas , Proteínas Recombinantes/farmacología , Ribonucleótidos/farmacología , Factor de Transcripción STAT3/metabolismo , Transducción de Señal/efectos de los fármacos , Proteína 3 Supresora de la Señalización de Citocinas , Proteínas Supresoras de la Señalización de Citocinas/metabolismo
5.
Diabetes ; 55(8): 2256-64, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16873688

RESUMEN

Berberine has been shown to have antidiabetic properties, although its mode of action is not known. Here, we have investigated the metabolic effects of berberine in two animal models of insulin resistance and in insulin-responsive cell lines. Berberine reduced body weight and caused a significant improvement in glucose tolerance without altering food intake in db/db mice. Similarly, berberine reduced body weight and plasma triglycerides and improved insulin action in high-fat-fed Wistar rats. Berberine downregulated the expression of genes involved in lipogenesis and upregulated those involved in energy expenditure in adipose tissue and muscle. Berberine treatment resulted in increased AMP-activated protein kinase (AMPK) activity in 3T3-L1 adipocytes and L6 myotubes, increased GLUT4 translocation in L6 cells in a phosphatidylinositol 3' kinase-independent manner, and reduced lipid accumulation in 3T3-L1 adipocytes. These findings suggest that berberine displays beneficial effects in the treatment of diabetes and obesity at least in part via stimulation of AMPK activity.


Asunto(s)
Berberina/uso terapéutico , Diabetes Mellitus/tratamiento farmacológico , Resistencia a la Insulina , Complejos Multienzimáticos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Células 3T3-L1 , Proteínas Quinasas Activadas por AMP , Adipocitos/efectos de los fármacos , Adipocitos/enzimología , Adipocitos/metabolismo , Tejido Adiposo/metabolismo , Animales , Berberina/administración & dosificación , Línea Celular , Dieta , Grasas de la Dieta/administración & dosificación , Metabolismo Energético/genética , Activación Enzimática/efectos de los fármacos , Regulación de la Expresión Génica , Técnica de Clampeo de la Glucosa , Transportador de Glucosa de Tipo 4/metabolismo , Lípidos/biosíntesis , Hígado/enzimología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Obesos , Fibras Musculares Esqueléticas/enzimología , Fibras Musculares Esqueléticas/metabolismo , Músculo Esquelético/metabolismo , Obesidad/tratamiento farmacológico , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación , Ratas , Ratas Wistar , Pérdida de Peso/efectos de los fármacos
6.
Cell Metab ; 7(5): 421-33, 2008 May.
Artículo en Inglés | MEDLINE | ID: mdl-18460333

RESUMEN

Insulin resistance is a common disorder caused by a wide variety of physiological insults, some of which include poor diet, inflammation, anti-inflammatory steroids, hyperinsulinemia, and dyslipidemia. The common link between these diverse insults and insulin resistance is widely considered to involve impaired insulin signaling, particularly at the level of the insulin receptor substrate (IRS). To test this model, we utilized a heterologous system involving the platelet-derived growth factor (PDGF) pathway that recapitulates many aspects of insulin action independently of IRS. We comprehensively analyzed six models of insulin resistance in three experimental systems and consistently observed defects in both insulin and PDGF action despite a range of insult-specific defects within the IRS-Akt nexus. These findings indicate that while insulin resistance is associated with multiple deficiencies, the most deleterious defects and the origin of insulin resistance occur independently of IRS.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/fisiología , Hiperinsulinismo/etiología , Hipoglucemiantes/farmacología , Resistencia a la Insulina , Insulina/farmacología , Adipocitos/citología , Adipocitos/metabolismo , Animales , Células Cultivadas , Prueba de Tolerancia a la Glucosa , Transportador de Glucosa de Tipo 4/metabolismo , Immunoblotting , Inflamación , Proteínas Sustrato del Receptor de Insulina , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Mioblastos/citología , Mioblastos/metabolismo , Estrés Oxidativo , Palmitatos/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Transporte de Proteínas , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas , Transducción de Señal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA